Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CorMedix Inc stock logo
CRMD
CorMedix
$13.69
+1.0%
$12.28
$5.10
$17.43
$1.01B1.713.29 million shs3.47 million shs
Immunome, Inc. stock logo
IMNM
Immunome
$10.30
+3.5%
$9.69
$5.15
$16.73
$866.10M1.93605,789 shs1.04 million shs
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
$9.74
+0.5%
$10.30
$3.90
$14.67
$941.12M1.691.32 million shs531,437 shs
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
$3.61
+4.9%
$3.31
$2.58
$4.92
$232.47M191,854 shs47,138 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CorMedix Inc stock logo
CRMD
CorMedix
+0.96%+5.88%+17.81%+10.76%+173.25%
Immunome, Inc. stock logo
IMNM
Immunome
+3.52%+0.19%-10.04%+21.32%-32.24%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
+0.52%+0.83%-17.46%+53.39%-0.71%
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
+4.94%+4.03%0.00%+26.67%+4.64%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CorMedix Inc stock logo
CRMD
CorMedix
2.6959 of 5 stars
3.41.00.00.03.30.01.9
Immunome, Inc. stock logo
IMNM
Immunome
1.9039 of 5 stars
3.50.00.00.02.72.50.0
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
4.7698 of 5 stars
4.53.00.04.42.43.30.6
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
3.0034 of 5 stars
3.55.00.00.02.70.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CorMedix Inc stock logo
CRMD
CorMedix
2.88
Moderate Buy$16.7122.09% Upside
Immunome, Inc. stock logo
IMNM
Immunome
3.00
Buy$22.50118.45% Upside
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
2.90
Moderate Buy$17.6380.95% Upside
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
3.00
Buy$8.00121.61% Upside

Current Analyst Ratings Breakdown

Latest SOPH, IMNM, CRMD, and ORIC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/22/2025
Immunome, Inc. stock logo
IMNM
Immunome
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$18.00
8/14/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.00
8/14/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$22.00 ➝ $19.00
8/13/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
8/12/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
8/8/2025
CorMedix Inc stock logo
CRMD
CorMedix
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $17.00
8/7/2025
Immunome, Inc. stock logo
IMNM
Immunome
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$23.00 ➝ $22.00
8/7/2025
Immunome, Inc. stock logo
IMNM
Immunome
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$21.00
7/8/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
6/30/2025
CorMedix Inc stock logo
CRMD
CorMedix
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/30/2025
CorMedix Inc stock logo
CRMD
CorMedix
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CorMedix Inc stock logo
CRMD
CorMedix
$43.47M23.51N/AN/A$2.96 per share4.63
Immunome, Inc. stock logo
IMNM
Immunome
$9.04M99.17N/AN/A$3.09 per share3.33
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/AN/AN/AN/A$3.34 per shareN/A
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
$65.17M3.74N/AN/A$1.13 per share3.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CorMedix Inc stock logo
CRMD
CorMedix
-$17.93M$0.7518.2514.56N/A42.11%42.73%34.19%10/29/2025 (Estimated)
Immunome, Inc. stock logo
IMNM
Immunome
-$292.96M-$3.08N/AN/AN/A-1,687.08%-76.10%-65.14%N/A
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$127.85M-$1.89N/AN/AN/AN/A-51.75%-47.09%N/A
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
-$62.49M-$0.44N/AN/AN/A-40.99%-30.69%-17.39%11/4/2025 (Estimated)

Latest SOPH, IMNM, CRMD, and ORIC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$0.46-$0.47-$0.01-$0.47N/AN/A
8/7/2025Q2 2025
CorMedix Inc stock logo
CRMD
CorMedix
$0.20$0.28+$0.08$0.28$29.88 million$39.74 million
8/6/2025Q2 2025
Immunome, Inc. stock logo
IMNM
Immunome
-$0.52-$0.50+$0.02-$0.50$1.03 million$4.02 million
8/5/2025Q2 2025
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
-$0.25$0.33+$0.58$0.33$17.49 million$18.32 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CorMedix Inc stock logo
CRMD
CorMedix
N/AN/AN/AN/AN/A
Immunome, Inc. stock logo
IMNM
Immunome
N/AN/AN/AN/AN/A
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/AN/AN/AN/AN/A
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CorMedix Inc stock logo
CRMD
CorMedix
N/A
7.82
7.52
Immunome, Inc. stock logo
IMNM
Immunome
N/A
12.13
12.13
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/A
16.13
16.13
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
0.62
3.39
3.21

Institutional Ownership

CompanyInstitutional Ownership
CorMedix Inc stock logo
CRMD
CorMedix
34.18%
Immunome, Inc. stock logo
IMNM
Immunome
44.58%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
95.05%
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
31.59%

Insider Ownership

CompanyInsider Ownership
CorMedix Inc stock logo
CRMD
CorMedix
5.30%
Immunome, Inc. stock logo
IMNM
Immunome
7.69%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
6.82%
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
4.88%
CompanyEmployeesShares OutstandingFree FloatOptionable
CorMedix Inc stock logo
CRMD
CorMedix
3074.65 million70.69 millionOptionable
Immunome, Inc. stock logo
IMNM
Immunome
4087.04 million80.35 millionOptionable
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
8097.12 million90.50 millionOptionable
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
52067.58 million64.28 millionNot Optionable

Recent News About These Companies

SOPHiA GENETICS SA: Positive Earnings Call Highlights
SOPHiA GENETICS Reports Second Quarter 2025 Results
An end to an era: Supreme Court won't review IVF mixup ruling
M42, partners launch liquid biopsy testing in UAE

New MarketBeat Followers Over Time

Media Sentiment Over Time

CorMedix stock logo

CorMedix NASDAQ:CRMD

$13.69 +0.13 (+0.96%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$13.85 +0.16 (+1.17%)
As of 08/22/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Immunome stock logo

Immunome NASDAQ:IMNM

$10.30 +0.35 (+3.52%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$10.30 +0.00 (+0.05%)
As of 08/22/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Oric Pharmaceuticals stock logo

Oric Pharmaceuticals NASDAQ:ORIC

$9.74 +0.05 (+0.52%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$9.73 -0.01 (-0.10%)
As of 08/22/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

SOPHiA GENETICS stock logo

SOPHiA GENETICS NASDAQ:SOPH

$3.61 +0.17 (+4.94%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$3.60 -0.01 (-0.42%)
As of 08/22/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.